Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul S Covington

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Clinical Therapeutics|May 13, 2014
Item-level assessment of the irritable bowel syndrome quality of life questionnaire in patients with diarrheal irritable bowel syndromeDavid A Andrae, Paul S Covington, Donald L Patrick
Health and Quality of Life Outcomes|December 17, 2013
Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patientsDavid A Andrae, Donald L Patrick, Douglas A Drossman, et al.
Journal of Clinical Pharmacology|July 19, 2017
Effect of Hepatic Impairment on Eluxadoline PharmacokineticsThomas C Marbury, Jolene Kay Berg, Leonard S Dove, et al.
Neurogastroenterology and Motility|January 28, 2020
Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D: Additional post hoc analyses of Phase 3 trialsAnthony J Lembo, Paul S Covington, Leonard S Dove, et al.
Clinical Pharmacology in Drug Development|April 17, 2018
Evaluation of Eluxadoline Effect on Cardiac RepolarizationLaura Bonifacio, Thomas L Hunt, Gail McIntyre, et al.
Frontiers in Nutrition|February 15, 2017
Sphincter of Oddi Function and Risk Factors for DysfunctionElham Afghani, Simon K Lo, Paul S Covington, et al.
The American Journal of Gastroenterology|October 6, 2017
Safety of Eluxadoline in Patients With IBS-D Without a GallbladderBrooks D Cash, Brian E Lacy, Philip S Schoenfeld, et al.
The American Journal of Gastroenterology|June 18, 2019
Response to LaiBrooks D Cash, Brian E Lacy, Philip S Schoenfeld, et al.
The American Journal of Gastroenterology|October 6, 2017
Response to Croteau and BarkinBrooks D Cash, Brian E Lacy, Philip S Schoenfeld, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 8, 2017
Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With DiarrheaReginald V Fant, Jack E Henningfield, Brooks D Cash, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Clinical Therapeutics|May 13, 2014
Item-level assessment of the irritable bowel syndrome quality of life questionnaire in patients with diarrheal irritable bowel syndromeDavid A Andrae, Paul S Covington, Donald L Patrick
Health and Quality of Life Outcomes|December 17, 2013
Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patientsDavid A Andrae, Donald L Patrick, Douglas A Drossman, et al.
Journal of Clinical Pharmacology|July 19, 2017
Effect of Hepatic Impairment on Eluxadoline PharmacokineticsThomas C Marbury, Jolene Kay Berg, Leonard S Dove, et al.
Neurogastroenterology and Motility|January 28, 2020
Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D: Additional post hoc analyses of Phase 3 trialsAnthony J Lembo, Paul S Covington, Leonard S Dove, et al.
Clinical Pharmacology in Drug Development|April 17, 2018
Evaluation of Eluxadoline Effect on Cardiac RepolarizationLaura Bonifacio, Thomas L Hunt, Gail McIntyre, et al.
Frontiers in Nutrition|February 15, 2017
Sphincter of Oddi Function and Risk Factors for DysfunctionElham Afghani, Simon K Lo, Paul S Covington, et al.
The American Journal of Gastroenterology|October 6, 2017
Safety of Eluxadoline in Patients With IBS-D Without a GallbladderBrooks D Cash, Brian E Lacy, Philip S Schoenfeld, et al.
The American Journal of Gastroenterology|June 18, 2019
Response to LaiBrooks D Cash, Brian E Lacy, Philip S Schoenfeld, et al.
The American Journal of Gastroenterology|October 6, 2017
Response to Croteau and BarkinBrooks D Cash, Brian E Lacy, Philip S Schoenfeld, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 8, 2017
Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With DiarrheaReginald V Fant, Jack E Henningfield, Brooks D Cash, et al.
Pageof 2